Clinical value of ALU concentration and integrity index for the early diagnosis of ovarian cancer: A retrospective cohort trial

CA125 amounts have a large overlap in ovarian cancer and benign diseases. We conducted a retrospective cohort trial to assess the clinical value of circulating cell-free DNA concentration and integrity index for the diagnosis of ovarian cancer. A total of 150 patients were recruited. Plasma samples...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Rong, PU, Wangyang, Zhang, Shuyun, Chen, Li, Zhu, Weipei, Xiao, Li, Xing, Chungen, Li, Kai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798773/
https://www.ncbi.nlm.nih.gov/pubmed/29401471
http://dx.doi.org/10.1371/journal.pone.0191756
Descripción
Sumario:CA125 amounts have a large overlap in ovarian cancer and benign diseases. We conducted a retrospective cohort trial to assess the clinical value of circulating cell-free DNA concentration and integrity index for the diagnosis of ovarian cancer. A total of 150 patients were recruited. Plasma samples of 24 ovarian cancer patients, 12 benign ovarian cysts, and 12 healthy controls were assessed. By amplifying short ALU-115 repeat and long ALU-219 fragments, circulating cell-free DNA concentrations and integrity index were measured. Plasma ALU-219 fragment levels and integrity index were significantly higher in the ovarian cancer group compared with the benign disease and healthy control groups (p = 0.023 and p = 0.004, respectively). These findings indicated that plasma ALU-219 levels and integrity may have a clinical value in the early diagnosis of ovarian cancer.

Ejemplares similares